Literature DB >> 28986023

Gallbladder and bile duct disease in Cystic Fibrosis.

David N Assis1, Dominique Debray2.   

Abstract

Cystic fibrosis (CF) is a multi-organ, clinically diverse disorder caused by mutations in the cystic fibrosis transmembrane conductance receptor (CFTR). Awareness of extra-pulmonary manifestations, including gastrointestinal and hepatobiliary disturbances, is an increasingly important part of providing high-quality care to patients with CF. Furthermore, biliary disorders, including gallbladder and bile duct disease, are common complications of CF. Therefore, a thorough understanding and efficient clinical evaluation of the gallbladder and biliary tree is an important aspect of integrated care for the patient with CF in order to prevent progression of undetected pathology. This best practice article summarizes the basis for gallbladder and bile duct pathology, describes the context and clinical presentation of biliary disease, and provides recommended approaches to delivery of high-quality care for patients with CF.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile Duct; Biliary; Cholestasis; Cystic fibrosis; Gallbladder

Mesh:

Year:  2017        PMID: 28986023     DOI: 10.1016/j.jcf.2017.07.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).

Authors:  Anke Jaudszus; Elisa Zeman; Tatjana Jans; Elena Pfeifer; Harold Tabori; Christin Arnold; Ruth K Michl; Michael Lorenz; Natalie Beiersdorf; Jochen G Mainz
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

2.  Anion Transport Across Human Gallbladder Organoids and Monolayers.

Authors:  Keyan Zarei; Ian M Thornell; David A Stoltz
Journal:  Front Physiol       Date:  2022-05-24       Impact factor: 4.755

Review 3.  Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis.

Authors:  Daniel R Ludwig; Mark A Anderson; Malak Itani; Kedar G Sharbidre; Neeraj Lalwani; Raj M Paspulati
Journal:  Abdom Radiol (NY)       Date:  2022-05-18

Review 4.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.

Authors:  Renée V E Dagenais; Victoria C H Su; Bradley S Quon
Journal:  J Clin Med       Date:  2020-12-23       Impact factor: 4.241

Review 5.  Cystic fibrosis associated liver disease in children.

Authors:  Joseph J Valamparampil; Girish L Gupte
Journal:  World J Hepatol       Date:  2021-11-27

6.  Identification of signature of gene expression in biliary atresia using weighted gene co-expression network analysis.

Authors:  Yongliang Wang; Hongtao Yuan; Maojun Zhao; Li Fang
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

7.  Liver X receptor β regulates bile volume and the expression of aquaporins and cystic fibrosis transmembrane conductance regulator in the gallbladder.

Authors:  Nathan Sweed; Hyun-Jin Kim; Kjell Hultenby; Rodrigo Barros; Paoo Parini; Valentina Sancisi; Birgitta Strandvik; Chiara Gabbi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-07-14       Impact factor: 4.871

8.  Systematic genetic analysis of the MHC region reveals mechanistic underpinnings of HLA type associations with disease.

Authors:  Matteo D'Antonio; Joaquin Reyna; David Jakubosky; Margaret Kr Donovan; Marc-Jan Bonder; Hiroko Matsui; Oliver Stegle; Naoki Nariai; Agnieszka D'Antonio-Chronowska; Kelly A Frazer
Journal:  Elife       Date:  2019-11-20       Impact factor: 8.713

9.  Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model.

Authors:  Keyan Zarei; Mallory R Stroik; Nick D Gansemer; Andrew L Thurman; Lynda S Ostedgaard; Sarah E Ernst; Ian M Thornell; Linda S Powers; Alejandro A Pezzulo; David K Meyerholz; David A Stoltz
Journal:  Lab Invest       Date:  2020-07-27       Impact factor: 5.502

10.  Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with Vitamin K2 in Cystic Fibrosis: A Randomized Multi-Center Trial.

Authors:  Jan Krzysztof Nowak; Patrycja Krzyżanowska-Jankowska; Sławomira Drzymała-Czyż; Joanna Goździk-Spychalska; Irena Wojsyk-Banaszak; Wojciech Skorupa; Ewa Sapiejka; Anna Miśkiewicz-Chotnicka; Jan Brylak; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.